Developing and testing new oligonucleotides for medical use
Official title: MANUFACTURE AND PRECLINICAL TESTING OF SITE BLOCKING OLIGONUCLEOTIDES (SBO)
Funded at Advanced Bioscience Laboratories, INC. · NIH-11211981 · Data updated 2026-11-12
This study is working on creating new types of medicines that target specific genes, which could lead to better treatments for patients with various health conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Advanced Bioscience Laboratories, INC. NIH-funded |
| Lab location | 1 site (Kensington, United States) |
| Project start | February 9, 2024 |
| Project end | February 8, 2027 |
| Funding year | 2024 |
| Award (this year) | $1,899,037 |
| NIH project number | 75N95022D00023-0-759502400001-1 |
| Project ID | NIH-11211981 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be patients with conditions that could be treated with oligonucleotide therapies.
✕Less likely to help
Patients who do not have genetic conditions or who are not candidates for oligonucleotide treatments may not benefit from this research.
What this research studies
This research focuses on the manufacture and preclinical testing of site-blocking oligonucleotides, which are specialized molecules designed to interact with specific genetic sequences. The approach involves producing and qualifying master cell banks and viral stocks, developing analytical methods, and ensuring that the manufacturing process meets stringent quality standards. Patients may benefit from advancements in drug formulations that could lead to more effective treatments for various conditions. The research emphasizes aseptic processing to ensure the safety and efficacy of the drug products being developed.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and targeted therapies for patients with specific genetic conditions.
How similar studies have gone: Other research has shown promise in the development of oligonucleotide therapies, indicating a potential for success in this area.
Where this research is happening
-
Advanced Bioscience Laboratories, INC.
Kensington, United States Active
Researchers
- Principal investigator: Retterer, Cary — Advanced Bioscience Laboratories, INC.
- Study coordinator: Retterer, Cary
Related research
Other NIH-funded projects on the same topics.
-
Development of vaccines and biologics for infectious diseases
This study is working on creating new vaccines to help protect people from infectious diseases, and it aims to make sure these vaccines are safe and effective before they are approved for use.
-
Developing new vaccines and biologics for infectious diseases
This study is all about creating and improving vaccines to help protect people from tough infections, including those that are hard to treat and could be used in bioterrorism, so that patients can have better options for staying healthy.
-
Developing a vaccine to fight fungal infections
This study is working on a new vaccine to help protect people, especially those with weakened immune systems, from serious fungal infections like Candida auris and Cryptococcus neoformans, which can be tough to treat.
-
Identifying and testing a new antibody treatment for Duchenne Muscular Dystrophy.
This study is looking at a new treatment for Duchenne Muscular Dystrophy (DMD) using a special type of antibody, and it aims to make sure the drug is safe and works well before it can be tested in people like you.
-
Manufacturing a new treatment for pain management
This study is exploring a new way to help manage pain using a special compound called VHCA8*, and it's designed for people looking for better pain relief options that are safe and backed by science.
-
Developing a vaccine to fight Candida auris infections
This study is working on a new vaccine to help protect people, especially those with weakened immune systems, from a serious fungal infection called Candida auris, with hopes of making it safe and effective for future testing.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.